Having initiated the US clinical trial for its Xlucane (ranibizumab) biosimilar, Xbrane describes the competitive situation for the ophthalmology drug in the US and Europe as “promising”, detailing plans to launch in the second quarter of 2022. The Swedish biosimilars specialist also offers updates on the rest of its pipeline.
Xbrane has initiated the study for its Xlucane (ranibizumab) biosimilar candidate in the US, shortly after receiving clearance to do so.
In January, the US Food and Drug Administration (FDA) and the Central Ethics Committee in the US accepted Xbrane’s investigational...